Riskpilot← Back to searchSign inGet full accessSciensium AB
ABActiveOrg 5592785017Styrmansgatan 2 2trResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20200 employees
Revenue 2024
SEK 135K
-56% vs 2023
EBITDA margin
78.7%
+202% vs 2023
Equity ratio
52.7%
Financial strength
Net profit 2024
SEK 106K
+201% vs 2023
| Revenue | SEK 135K | -56% |
| EBITDA | SEK 106K | +202% |
| Net profit | SEK 106K | +201% |
| Total assets | SEK 1,9M | +6% |
| Equity | SEK 1M | +12% |
| Employees | 0 | — |
Legal name
Sciensium AB
Org number
5592785017
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
23 oktober 2020
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva innovations- och konsultverksamhet inom det medicinska området samt därmed förenlig verksamhet.
Address
Styrmansgatan 2 2tr
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 522 | 985 | 306 | 135 |
| Staff expenses | — | — | — | — |
| EBITDA | −4 | 5 | −104 | 106 |
| Depreciation & amort. | −0 | −0 | — | — |
| EBIT | −4 | 5 | −104 | 106 |
| Net financials | — | — | 0 | −0 |
| Profit before tax | −4 | 5 | −104 | 106 |
| Tax | −0 | −0 | — | −0 |
| Net profit | −4 | 5 | −104 | 106 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 346 | 2 008 | 1 806 | 1 906 |
| Equity | 21 | 1 003 | 899 | 1 004 |
| Long-term debt | 0 | 0 | — | — |
| Short-term debt | 325 | 1 005 | 908 | 902 |
| Total debt | 325 | 1 005 | 908 | 902 |
EBITDA margin
78.7%
This company
15.8%
Market median
+398% vs market
20212024
Equity ratio
52.7%
This company
38.2%
Market median
+38% vs market
20212024
Return on equity
10.5%
This company
18.4%
Market median
+43% vs market
20212024
Net profit margin
78.4%
This company
8.1%
Market median
+868% vs market
20212024
Asset turnover
0.07×
This company
1.12×
Market median
-94% vs market
20212024
Debt / equity
0.90×
This company
0.62×
Market median
+45% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-10-01 – 2021-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2025 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2022 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Deputy Board Member | 2025 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Sciensium AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mikael Åke Sandefeldt | Board of Directors | 0 companies |
| Nils Henrik Kristoffer Svensson | Deputy Board Member | 0 companies |
| Anna Elina Ulrika Jönsson | Deputy Board Member | 0 companies |
| Lina Anna Elisabeth Nordström | Deputy Board Member | 0 companies |
| Nina Marika Wodzinski | Board of Directors | 0 companies |
| Lars Anders Jönsson | Board of Directors | 0 companies |
| Henrik Daniel Karlsson | Deputy Board Member | 0 companies |
| Eva Renée Anelin Sandefeldt | Deputy Board Member | 0 companies |